The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Artificial Intelligence (AI) In Biopharmaceuticals Market Expected To Reach Based On Its 2026 Value?
The market for artificial intelligence (ai) in biopharmaceuticals has experienced significant expansion in recent years. This sector is anticipated to expand from $2.1 billion in 2025 to $2.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 33.0%. Historically, this growth has been driven by factors such as the early adoption of ai in pharma research, increasing computational power, rising investment in biopharmaceutical r&d, integration of omics data, and the growth of cloud-based data storage.
The artificial intelligence (ai) in biopharmaceuticals market size is projected to experience substantial expansion in the coming years. This market is set to reach $8.77 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 33.1%. This anticipated growth throughout the forecast period stems from factors such as advancements in machine learning algorithms, the expansion of ai-enabled lab equipment, wider adoption of predictive analytics, an increase in collaborative ai-biopharma platforms, and government incentives supporting ai-driven healthcare. Key trends shaping the forecast period encompass ai-driven drug discovery, predictive analytics applied to clinical trials, enhanced automation in laboratory processes, integration of real-world data, and the optimization of personalized treatments.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14251&type=smp
What Primary Drivers Are Shaping The Artificial Intelligence (AI) In Biopharmaceuticals Market?
The increasing incidence of chronic illnesses is projected to fuel the expansion of the artificial intelligence (AI) in biopharmaceuticals market moving forward. These long-term conditions typically advance gradually and can persist for years or even a lifetime. Their development stems from factors such as lifestyle choices, an aging demographic, genetic predispositions, and environmental influences. AI in biopharmaceuticals is increasingly utilized for managing chronic diseases due to its capacity to analyze vast amounts of diverse data, identify patterns, and personalize treatment approaches. For instance, in April 2025, data from the Centers for Disease Control and Prevention (CDC), a US-based federal agency, indicated that in 2023, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition. The prevalence was recorded as 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. As a result, the escalating prevalence of chronic diseases is a significant driver for the growth of artificial intelligence (AI) in the biopharmaceuticals market.
How Are Segments Identified Within The Artificial Intelligence (AI) In Biopharmaceuticals Market Segment Framework?
The artificial intelligence (ai) in biopharmaceuticals market covered in this report is segmented –
1) By Offering: Hardware, Software, Services
2) By Deployment: Cloud, On-Premises
3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies
4) By Application: Drug Discovery, Precision Medicine
5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes
Subsegments:
1) By Hardware: High-Performance Computing Systems, AI-Enabled Laboratory Equipment, Data Storage Solutions
2) By Software: Drug Discovery Platforms, Predictive Analytics Tools, Natural Language Processing Solutions
3) By Services: Consulting Services, Implementation And Integration Services, Data Management And Analytics Services, Training And Support Services
What Trends Are Affecting The Growth Of The Artificial Intelligence (AI) In Biopharmaceuticals Market?
Major companies in biopharmaceuticals utilizing artificial intelligence (AI) are concentrating on developing innovative advancements, such as AI-powered target and lead identification suites, to accelerate drug discovery and precision medicine, thereby transforming life sciences organizations. These solutions for drug discovery and precision medicine encompass a variety of innovative approaches to developing new drugs and tailoring treatments to individual patients. For instance, in May 2023, Google LLC, a US-based provider of cloud computing services, launched two new AI-powered tools called target and lead identification suites, designed to help researchers predict and understand the structure of proteins, which is a fundamental part of drug development. Additionally, this suite will assist researchers in ingesting, storing, analyzing, and sharing large amounts of genomic data, which is crucial for precision medicine. Also, these tools aim to streamline the drug discovery process, reduce costs, and bring new treatments to market faster. By providing efficient data management, accurate predictions of protein structures, and advanced genomic analysis capabilities, these tools aim to revolutionize drug development processes and improve patient outcomes.
Who Are The Companies Competing Within The Artificial Intelligence (AI) In Biopharmaceuticals Market?
Major companies operating in the artificial intelligence (ai) in biopharmaceuticals market are Exscientia Limited, DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.
Get The Full Artificial Intelligence (AI) In Biopharmaceuticals Market Report:
Which Region Represents The Largest Share Of The Artificial Intelligence (AI) In Biopharmaceuticals Market?
North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (ai) in biopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Artificial Intelligence (AI) In Biopharmaceuticals Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Biopharmaceuticals Market 2026, By The Business Research Company
Artificial Intelligence Ai In Biopharmaceuticals Market Report 2026
Artificial Intelligence In Drug Discovery Market Report 2026
Artificial Intelligence Ai In Precision Medicine Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model